Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma

1. diagnosis of primary HCC, confirmed histologically or clinically according to the criteria of the American Association for the Study of Liver Diseases 20;

2. presence of oligometastasis, the metastases found within three month of HCC diagnosis;

3. metastases with limited five sites and no more two organs involved, with a maximum diameter of ≤5cm;

4. receipt of Lenvatinib and PD-1 inhibitor as the first-line systemic therapy for a minimum of 3 months before study ablation, with controlled intrahepatic tumors and no progression of metastases. Controlled intrahepatic tumors were defined as those showing a partial or stable response according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST);

5. undergone locoregional treatments, including transarterial artery chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC);

6. classified as Child-Pugh class A or B and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;

7. no history of other malignancies.

8. life expectancy more than 3 months;

9. agreed to participated in this clinical trial;

10. Hemameba ≥3.0 x109/L, neutrophil ≥1.5x109/L, hemoglobin≥10.0 g/L, platelet≥100x 109/L, ALT; AST; bilirubin ≤1.5-fold normal, GFR≥60ml/min.

1. recurrent HCC;

2. advanced HCC Lenvatinib and PD-1 inhibitor treated with as second systemic therapy;

3. age < 18 years or > 75 years;

4. advanced HCC with more than five metastases;

5. no response to Lenvatinib;

6. metastases size > 5 cm;

7. life expectancy less than 3 months.